Luo Yufang, Guo Zi, He Honghui, Yang Youbo, Zhao Shaoli, Mo Zhaohui
Department of Endocrinology, Third Xiangya Hospital of Central South University & Diabetic Foot Research Center of Central South University, Changsha, Hunan Province 410013, China.
Int J Endocrinol. 2020 Oct 31;2020:2965175. doi: 10.1155/2020/2965175. eCollection 2020.
Metabolic surgery is an effective treatment for type 2 diabetes (T2D). At present, there is no authoritative standard for predicting postoperative T2D remission in clinical use. In general, East Asian patients with T2D have a lower body mass index and worse islet function than westerners. We aimed to look for clinical predictors of T2D remission after metabolic surgery in Chinese patients, which may provide insights for patient selection.
Patients with T2D who underwent metabolic surgery at the Third Xiangya Hospital between October 2008 and March 2017 were enrolled. T2D remission was defined as an HbA1c level below 6.5% and an FPG concentration below 7.1 mmol/L for at least one year in the absence of antidiabetic medications.
(1) Independent predictors of short-term T2D remission (1-2 years) were age and C-peptide area under the curve (C-peptide AUC); independent predictors of long-term T2D remission (4-6 years) were C-peptide AUC and fasting plasma glucose (FPG). (2) The optimal cutoff value for C-peptide AUC in predicting T2D remission was 30.93 ng/ml, with a specificity of 67.3% and sensitivity of 75.8% in the short term and with a specificity of 61.9% and sensitivity of 81.5% in the long term, respectively. The areas under the ROC curves are 0.674 and 0.623 in the short term and long term, respectively. (3) We used three variables (age, C-peptide AUC, and FPG) to construct a remission prediction score (ACF), a multidimensional 9-point scale, along which greater scores indicate a better chance of T2D remission. We compared our scoring system with other reported models (ABCD, DiaRem, and IMS). The ACF scoring system had the best distribution of patients and prognostic significance according to the ROC curves.
Presurgery age, C-peptide AUC, and FPG are independent predictors of T2D remission after metabolic surgery. Among these, C-peptide AUC plays a decisive role in both short- and long-term remission prediction, and the optimal cutoff value for C-peptide AUC in predicting T2D remission was 30.93 ng/ml, with moderate predictive values. The ACF score is a simple reliable system that can predict T2D remission among Chinese patients.
代谢手术是治疗2型糖尿病(T2D)的有效方法。目前,临床应用中尚无预测术后T2D缓解的权威标准。一般来说,东亚T2D患者的体重指数较低,胰岛功能比西方人差。我们旨在寻找中国患者代谢手术后T2D缓解的临床预测因素,这可能为患者选择提供参考。
纳入2008年10月至2017年3月在中南大学湘雅三医院接受代谢手术的T2D患者。T2D缓解定义为在无抗糖尿病药物治疗的情况下,糖化血红蛋白(HbA1c)水平低于6.5%且空腹血糖(FPG)浓度低于7.1 mmol/L至少1年。
(1)T2D短期缓解(1 - 2年)的独立预测因素是年龄和曲线下C肽面积(C肽AUC);T2D长期缓解(4 - 6年)的独立预测因素是C肽AUC和空腹血糖(FPG)。(2)预测T2D缓解的C肽AUC最佳截断值为30.93 ng/ml,短期特异性为67.3%,敏感性为75.8%,长期特异性为61.9%,敏感性为81.5%。短期和长期的ROC曲线下面积分别为0.674和0.623。(3)我们使用三个变量(年龄、C肽AUC和FPG)构建了一个缓解预测评分(ACF),这是一个多维9分制量表,分数越高表明T2D缓解的机会越大。我们将我们的评分系统与其他报道的模型(ABCD、DiaRem和IMS)进行了比较。根据ROC曲线,ACF评分系统的患者分布和预后意义最佳。
术前年龄、C肽AUC和FPG是代谢手术后T2D缓解的独立预测因素。其中,C肽AUC在短期和长期缓解预测中起决定性作用,预测T2D缓解的C肽AUC最佳截断值为30.93 ng/ml,具有中等预测价值。ACF评分是一个简单可靠的系统,可预测中国患者的T2D缓解情况。